NYSE$LH

Laboratory Corp Of America Holdings · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Labcorp's Q2 2024 earnings showcased revenue and EPS growth, driven by organic growth and strategic acquisitions.

Labcorp reported a strong second quarter in 2024, with revenue increasing by 6.2% to $3.22 billion and diluted EPS rising to $2.43. The company's performance was driven by organic growth in its base business and contributions from acquisitions. Labcorp has updated its full-year guidance to reflect this strong performance and the acquisition of Invitae.

  • Revenue increased by 6.2% to $3.22 billion compared to Q2 2023.
  • Diluted EPS increased to $2.43, up from $1.74 in the same quarter last year.
  • Adjusted EPS increased to $3.94, compared to $3.42 in Q2 2023.
  • Free cash flow increased significantly to $432.9 million, compared to $58.2 million in the second quarter of 2023.

Headline financials

Total Revenue

$3.22B

Previous: $3.03B+6.2%
EPS

$2.43

Previous: $3.42-28.9%
Capital Expenditures

-$262M

Previous: $103M-353.6%
Free Cash Flow

-$56.7M

Previous: $177M-132.0%
Net Income

$205M

Previous: $155M+32.3%
Operating Income

$295M

Previous: $266M+10.7%
Gross Profit

$926M

Previous: $842M+10.0%
Cash & Equivalents

$265M

Previous: $1.9B-86.0%
Total Assets

$16.7B

Previous: $17.7B-5.6%
Stock-Based Comp

$30.8M

Previous: $34.4M-10.5%

Revenue & EPS history

LabCorp · Revenue · Quarterly

$3.22B

Q2 2024+6.2%vs Q2 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

LabCorp · $3.06B total across 2 segments · Q3 2023

  • Diagnostics Laboratories
    $2.34B+6.0%
  • Biopharma Laboratory Services
    $719M-48.8%

Forward guidance

Labcorp is updating its 2024 full-year guidance to reflect its second-quarter performance, the acquisition of Invitae, and its full-year outlook.

Tailwinds

  • Revenue range of 6.4% to 7.5%, which includes an Invitae impact of approximately 1.0%.
  • Diagnostics Laboratories revenue growth between 6.9% and 7.9%.
  • Biopharma Laboratory Services revenue growth between 3.7% and 5.0%.
  • Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40.
  • Free Cash Flow of $0.85 billion to $1.00 billion, which includes Invitae cash usage of ~$150 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

-0.3%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-0.9%

Avg return

30 days after

48%

35 / 73 earnings

Positive

+9.5%

Q2 2024

Best reaction

-10.4%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.0%+0.0%+1.3%
Q4 2025-2.1%+0.0%-6.6%
Q3 2025-5.7%-7.9%-2.7%
Q2 2025-0.5%+1.2%+2.0%
Q1 2025+4.7%+7.9%+7.5%
Q4 2024-0.9%-1.9%+1.2%
Q3 2024+4.0%+3.7%+9.0%
Q2 2024+9.5%+4.8%+6.7%
Q1 2024-4.6%-3.2%-4.0%
Q4 2023-5.0%-5.5%-8.3%
Q3 2023+0.6%+1.0%+7.6%
Q2 2023-1.9%-2.4%-3.0%
Q1 2023-4.6%-2.5%-8.2%
Q4 2022+3.2%-0.4%-14.1%
Q3 2022-2.5%-3.2%+5.0%
Q2 2022+5.1%+1.2%-8.1%
Q1 2022-5.0%-3.1%+1.9%
Q4 2021-1.9%-6.0%-5.7%
Q3 2021+2.3%+2.0%+3.1%
Q2 2021+4.6%+6.0%+6.1%
Q1 2021+1.2%+4.1%+4.5%
Q4 2020+4.0%+3.1%+4.1%
Q3 2020+1.0%-1.1%-2.7%
Q2 2020-3.3%-4.2%-13.4%
Q1 2020-6.5%-10.4%-0.4%
Q4 2019+4.1%+1.8%-19.5%
Q3 2019-2.0%-2.3%+0.4%
Q2 2019-6.5%-4.2%-6.9%
Q1 2019+3.7%+6.1%+5.1%
Q4 2018+2.5%+3.8%+3.7%
Q3 2018-7.1%-6.2%-4.1%
Q2 2018-5.4%-6.4%-5.3%
Q1 2018+3.9%+2.8%+9.7%
Q4 2017+3.9%+3.0%+5.9%
Q3 2017+1.7%+2.2%+0.2%
Q2 2017+2.0%+1.3%-1.4%
Q1 2017-4.1%-3.1%-1.9%
Q4 2016+2.4%+2.4%+5.4%
Q3 2016-10.4%-9.4%-7.9%
Q2 2016+0.4%+1.2%-1.4%
Q1 2016+4.1%
Q4 2015+2.8%
Q3 2015+7.8%
Q2 2015+3.8%
Q1 2015-2.7%
Q4 2014+4.9%
Q3 2014+3.5%
Q2 2014-0.5%
Q1 2014-0.7%
Q4 2013+1.1%
Q3 2013-3.2%
Q2 2013+0.0%
Q1 2013+0.7%
Q4 2012-1.7%
Q3 2012-4.0%
Q2 2012-9.0%
Q1 2012-3.4%
Q4 2011+2.2%
Q3 2011-6.6%
Q2 2011-0.6%
Q1 2011+1.4%
Q4 2010-0.2%
Q4 2007-0.2%
Q3 2010+1.6%
Q2 2010+0.9%
Q1 2009+1.8%
Q1 2010+1.6%
Q4 2009-0.4%
Q2 2008-1.6%
Q3 2009-1.6%
Q3 2008-1.6%
Q4 2008-1.4%
Q2 2009-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro